Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was established in 2009, formerly known as Ikaria Development LLC, and changed to its current name in 2014. It is headquartered in Hampton, New Jersey and has 20 full-time employees. A company specializing in the treatment of heart and lung diseases.
Bellerophon Therapeutics (BLPH):
Bellerophon Therapeutics is a clinical therapeutic drug company dedicated to the development of drugs and equipment for the treatment of heart and lung diseases.
Bellerophon Therapeutics Company provides INOpulse, a pulsed nitric oxide delivery device, currently (2019) is undergoing phase III clinical trials for the treatment of pulmonary hypertension; the product has completed the treatment of idiopathic pulmonary fibrosis-related Phase II clinical trial of pulmonary hypertension related to chronic obstructive pulmonary disease and pulmonary hypertension.
Bellerophon products are also used for other symptoms of pulmonary hypertension.
Bellerophon treats Bellerophon Therapeutics (BLPH) inflation:
BLPH was listed on the Nasdaq Stock Exchange on 2015-02-14 with an issue price of US$12.